Mission
Solving high-mortality disease
Solving high-mortality diseases and severe social problems with AI and smart technologies.
Bio AI & Smart Device R&D
Connecting Life, AI & Smart Devices
An innovative biotech company solving intractable disease and critical social challenges with AI and smart devices
We integrate multimodal biosensing in smart glasses, automated emergency-medical linkage and autonomous-driving safety into a single platform.
2026 .05
Established
12
Patents filed (6 domestic · 6 PCT)
10 +
Partner countries
1
JoongAng Innovative IT Award
CH
CSEM SA
JP
IT Lab Co., Ltd.
JP
OfficeHase Co., Ltd.
CN
Shanghai Upper Bio-Tech Pharma
SG
BamX Pte Ltd.
KR
Seegene Co., Ltd.
Executive Summary
Executive Summary
An innovative biotech company solving intractable disease and critical social challenges with AI and smart devices.
Core Business
Bio AI smart glasses R&D
Bio AI smart glasses R&D, plus bio and medical device sales and trade.
Technology
AI early diagnosis & autonomy
AI-based early disease diagnosis and agents, plus drowsy-driving prevention and autonomous-driving technology.
Market
Entering convergence markets
Entering the global IVD, smart glasses and autonomous-driving convergence markets.
Partners
Partners in 10+ countries
R&D, marketing and sales collaboration with partners across 10+ countries including Korea, Japan, China, Switzerland and Singapore.
IP Status
6 domestic · 6 PCT filings
Two filings for smart glasses and autonomous driving; two each for Bio AI diagnosis and AI agents.
Core Technology
Technology
AI-based early disease diagnosis and agents, plus drowsy-driving prevention and autonomous-driving technology.
01
Bio AI Smart Glasses Diagnostic System
An AI-driven medical diagnostic platform worn as eyewear
Multimodal sensors inside the frame continuously measure heart rate, blood pressure, SpO₂, ECG and EEG, while an on-device AI chip flags abnormalities in real time on the AR HUD.
Multimodal biometric authentication
Critical commands execute only when the user’s voice matches iris, fingerprint or dermal recognition.
Early disease diagnosis
Early detection of ocular, diabetic, hypertensive, cardiovascular, cerebral and respiratory disease.
Emergency response
On cardiac arrest or an accident, emergency services and hospitals are called automatically with location and video attached.
Personalised care
Medical records and live data are analysed together to suggest treatment.
02
Anti-Drowsiness & AI Autonomous Driving
Technology that prevents tens of thousands of drowsy-driving casualties a year
Smart-glasses cameras track eye, eyelid and pupil changes while EEG, PPG, ECG and skin-conductance sensors confirm drowsiness — the vehicle then switches to autonomous mode and executes deceleration, a shoulder pull-over, a cool-air blast and alerts to surrounding vehicles.
Ocular tracking
Micro-changes in eyes, eyelids and pupils are analysed in real time.
EEG measurement
Frame-mounted sensors measure EEG through scalp contact.
Autonomous takeover
Once drowsiness is confirmed the vehicle takes over driving itself.
Alerts to nearby vehicles
Surrounding vehicles are warned the moment the car decelerates and stops.
- Biosignal detection
- AI drowsiness check
- Autonomous takeover
- Decelerate & stop
- Alert nearby vehicles
03
AI Agent (Non-invasive Autonomous Agent)
A single spoken command handles daily life, work, medical and financial tasks
A non-invasive agent that autonomously drives existing apps and the web without modifying any system, combining generative-AI language understanding with robotic autonomous execution.
Autonomous driving sync
Voice control of parking, vehicle summoning, climate, engine and infotainment.
Office assistant
Automates shopping, clinic bookings, taxi hailing, meeting minutes, document scans and file transfers.
Multilingual interpretation
Camera text recognition plus real-time simultaneous interpretation.
Emergency linkage
Auto-connects to the emergency room, police and fire services for cardiac arrest and for traffic, crime or fire incidents — replacing the limits of a phone call with automatic detection and instant reporting within the golden hour.
- Generative AI · language understanding
- AI robot · autonomous app & web execution
- Non-invasive agent · no system modification
Competitive Edge
Competitive Edge
Partner With Us
Fundus-based disease diagnosis
- Big Tech
- None
- Medical AR
- Partial
- GeniusMed
- Strong
Multi-biosignal integration
- Big Tech
- Partial
- Medical AR
- None
- GeniusMed
- Strong
Emergency rescue & medical service auto-linkage
- Big Tech
- None
- Medical AR
- None
- GeniusMed
- Strong
Smart mobility
- Big Tech
- None
- Medical AR
- None
- GeniusMed
- Strong
Iris & voice multimodal security
- Big Tech
- Partial
- Medical AR
- None
- GeniusMed
- Strong
All-day lightweight form factor
- Big Tech
- Strong
- Medical AR
- None
- GeniusMed
- Strong
| Category | Big Tech Meta · Apple | Medical AR MediThinQ etc. | GeniusMed |
|---|---|---|---|
| Fundus-based disease diagnosis | None | Partial | Strong |
| Multi-biosignal integration | Partial | None | Strong |
| Emergency rescue & medical service auto-linkage | None | None | Strong |
| Smart mobility | None | None | Strong |
| Iris & voice multimodal security | Partial | None | Strong |
| All-day lightweight form factor | Strong | None | Strong |
USP — Medical-specialised fundus diagnosis +
integrated multi-sensor + EMS linkage + smart mobility + multimodal security.
Business Model
Business
Pillar 1
Bio & medical device sales and trade
Our current primary revenue base, generating income immediately.
- Domestic and overseas distribution of IVD diagnostic products
- Biopharma and medical-device import/export trade
- Leveraging partner channels in China, Japan and Singapore
Pillar 2
Bio AI & smart device R&D
Licensing and productisation in the mid term; recurring SaaS and platform subscriptions in the long term.
- Productisation of AI smart glasses and ECG patches for B2B/B2C sales
- Licensing of drowsiness accident-prevention technology across automotive, aviation, maritime and industrial sites
- Bio AI disease-diagnosis SaaS subscription model
- AI agent platform API provision
Short term — medical device trade
Mid term — licensing &
productisation
Long term — recurring SaaS
Market Opportunity
Market Opportunity
Entering the global IVD, smart glasses and autonomous-driving convergence markets.
$113B+
Global IVD market
~6% CAGR, 2028E
$52B+
Smart glasses market
~25% CAGR, 2030E
$550B+
Autonomous driving market
~35% CAGR, 2030E
291T
2040 smart glasses market (KRW)
HSBC Global Research
+322%
2025 AI-glasses shipment growth
Year on year · Omdia
15M
2026E AI-glasses shipments
Units
Global Partnership Network
Global Partner Network
R&D, marketing and sales collaboration with partners across 10+ countries including Korea, Japan, China, Switzerland and Singapore.
CH
R&D
CSEM SA
Switzerland
A non-profit research and technology organisation founded by the Swiss federal government in 1984. Around 640 researchers from 45 countries, headquartered in Neuchâtel, lead in ultra-low-power chips, biosensors and wearable vital-sign monitoring.
www.csem.ch
JP
R&D
IT Lab Co., Ltd.
Japan
Development partner for in-vitro diagnostic devices and biopharmaceuticals.
JP
Marketing
OfficeHase Co., Ltd.
Japan
Marketing partner for the Japanese market.
CN
R&D · Marketing
Shanghai Upper Bio-Tech Pharma
China
IVD medical device developer and China marketing partner. Listed on the Beijing Stock Exchange.
SG
Marketing
BamX Pte Ltd.
Singapore
Marketing partner for the ASEAN region.
KR
R&D · Sales
Seegene Co., Ltd.
Korea
Partner for IVD medical device development and sales.
Global R&D Collaboration
CSEM MoU & Eurostars joint proposal
A memorandum of understanding with Switzerland's CSEM was signed electronically on 2 July 2026 and is valid for two years. The parties jointly develop vital-sign monitoring — heart rate, HRV, SpO₂, blood pressure and EEG — integrated into smart glasses. GeniusMed leads the project and system integration; CSEM contributes optical sensing, biopotentials and digital-health R&D.
A joint proposal for the 11th Eurostars call is being prepared with CSEM (deadline 10 September 2026). If selected, the Korean SME is funded for up to 67% of project cost through the Korea Institute for Advancement of Technology, strengthening eligibility for global government R&D funding.
CSEM Profile
- Founded
- 1984
- Researchers
- 640+
- Countries
- 45
- Headquarters
- Neuchâtel
CEO Brian Lee · Jens Krauss (VP MedTech BU, CSEM)
Awards
2026 Innovative IT Award
The JoongAng Newspaper · 2026.08
Awarded in the Industrial Convergence & Smart Technology category for the innovation of our Bio AI smart glasses and drowsy-driving prevention technology.
View All
Roadmap & Targets
Growth Roadmap
2026
IP rights & global collaboration
- Full patent filing for Bio AI diagnosis & AI agents
- Joint Eurostars proposal with CSEM
- Recruiting core talent
2027
Prototype & clinical validation
- Target 95% AI diagnostic accuracy
- First-generation integrated device prototype and medical-data AI
- Clinical validation at SNU Bundang Hospital, Severance Hospital and Mayo Clinic
2028+
Global commercialization
- PCT-based entry into the US, EU, China, Japan and India
- Ramp-up of approvals, SaaS and licensing revenue
- Groundwork for a technology-track IPO
Motion
Videos
Newsroom
Newsroom
news
2026.08.05
Six PCT international filings completed
International filing is complete for two smart-glasses and autonomous-driving inventions and four Bio AI diagnosis and AI agent inventions.
Read More
award
2026.08.01
GeniusMed wins the JoongAng Ilbo 2026 Innovative IT Grand Prize
Recognised in the Industrial Convergence & Smart Technology category for Bio AI smart glasses and drowsy-driving prevention.
Read More
news
2026.07.02
Joint development MoU signed with Switzerland’s CSEM
A two-year agreement to integrate heart rate, HRV, SpO₂, blood pressure and EEG monitoring into smart glasses.
Read MoreInvestment Proposal
Shape the future of healthcare and mobility with GeniusMed
Proprietary patents, a global partner network, a hybrid revenue model and entry into massive markets — four axes of growth.
Patents Filed
6 + 6 PCT
Global Partners
10+
Business
Trade · License · SaaS
Investors
IVD · AR · Autonomy